ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment

• DOI: 10.1097/fpc.0b013e32833db216
• Publication Date: 2010-09-21T11:30:30Z
• Authors: Keh-Ming Lin; Yen-Feng Chiu; I-Ju Tsai; Chia-Hui Chen; Winston W. Shen; Shu Chih Liu; Shao-Chun Lu; Chia-Yih Liu; Mei-Chun Hsiao; Hwa-Sheng Tang; Shen-Ing Liu; Liang-Huey Chang; Chi-Shin Wu; Hsiao-Hui Tsou; Ming-Hsien Tsai; Chun-Yu Chen; Su-Mei Wang; Hsiang-Wei Kuo; Ya-Ting Hsu; Yu-Li Liu
• Keywords: Escitalopram

Objective ATP-binding cassette, sub-family B (MDR/TAP), member 1 (ABCB1) is a drug transporter protein expressed on the epithelial cells of intestine and endothelial blood–brain barrier. Intestinal ABCB1 actively transports drugs from cell membrane prevents them entering blood stream whereas barrier central nervous system. In this study, we tested whether genetic polymorphisms within gene are associated with severity depression effectiveness antidepressant, escitalopram (S-CIT), in treating major depressive disorder (MDD). Methods Twenty single nucleotide were selected genotyped 100 MDD patients who had undergone S-CIT treatment continuously for 8 weeks. The serum concentrations its metabolites (S-desmethylcitalopram S-didesmethylcitalopram) then measured at weeks 2, 4, 8. Results genotypes rs1922242 (P=0.0028) rs1202184 (P=0.0021) showed significant association symptoms as assessed by Hamilton Rating Scale Depression adjusted Anxiety. haplotype block, rs1882478-rs2235048-rs2235047-rs1045642-rs6949448 (from intron 27 to 26), was found strongly remission rate (global P=0.003, d.f.=69) which T-T-T-C-C slower (P=0.001). haplotypes may not be indicators or anxiety. Conclusion Our findings suggest that likely response MDD.